Terilyn J. Monroe
Known title: Chief People OfficerCIK: 0001652956
Associated companies
Transaction History
| GH | ▲ Buy | Option Exercise | 2,659 | $0 | 10/1/2026 | View on chart |
| GH | ▲ Buy | Option Exercise | 1,360 | $0 | 10/1/2026 | View on chart |
| GH | ▼ Sell | Tax Withholding | 2,098 | $367K | 10/1/2026 | View on chart |
| GH | ▼ Sell | Open Market | 3,704 | $605K | 8/12/2026 | View on chart |
| GH | ▼ Sell | Open Market | 19,014 | $3.1M | 8/12/2026 | View on chart |
| GH | ▼ Sell | Open Market | 400 | $67K | 8/12/2026 | View on chart |
| GH | ▼ Sell | Open Market | 9,934 | $1.6M | 8/12/2026 | View on chart |
| GH | ▲ Buy | Option Exercise | 14,012 | $401K | 8/12/2026 | View on chart |
| GH | ▼ Sell | Open Market | 13,248 | $2.2M | 8/12/2026 | View on chart |
| GH | ▲ Buy | Option Exercise | 32,288 | $650K | 8/12/2026 | View on chart |
| GH | ▲ Buy | Option Exercise | 2,659 | $0 | 7/1/2026 | View on chart |
| GH | ▲ Buy | Option Exercise | 1,361 | $0 | 7/1/2026 | View on chart |
| GH | ▼ Sell | Tax Withholding | 2,099 | $358K | 7/1/2026 | View on chart |
| GH | ▼ Sell | Open Market | 3,832 | $355K | 4/6/2026 | View on chart |
| GH | ▲ Buy | Option Exercise | 2,660 | $0 | 4/1/2026 | View on chart |
| GH | ▲ Buy | Option Exercise | 5,359 | $0 | 4/1/2026 | View on chart |
| GH | ▼ Sell | Tax Withholding | 4,187 | $382K | 4/1/2026 | View on chart |
| GH | ▼ Sell | Open Market | 3,619 | $411K | 1/21/2026 | View on chart |
| GH | ▼ Sell | Open Market | 1,703 | $191K | 1/21/2026 | View on chart |
| GH | ▼ Sell | Open Market | 3,249 | $376K | 1/21/2026 | View on chart |
| GH | ▲ Buy | Option Exercise | 17,379 | $0 | 1/15/2026 | View on chart |
| GH | ▼ Sell | Tax Withholding | 8,808 | $986K | 1/15/2026 | View on chart |
| GH | ▼ Sell | Open Market | 3,632 | $409K | 1/7/2026 | View on chart |
| GH | ▼ Sell | Open Market | 88 | $10K | 1/7/2026 | View on chart |
| GH | ▼ Sell | Open Market | 6,311 | $705K | 1/7/2026 | View on chart |
| GH | ▲ Buy | Option Exercise | 14,896 | $0 | 1/1/2026 | View on chart |
| GH | ▼ Sell | Tax Withholding | 7,524 | $769K | 1/1/2026 | View on chart |
| GH | ▲ Buy | Option Exercise | 2,659 | $0 | 1/1/2026 | View on chart |
| GH | ▼ Sell | Open Market | 18,576 | $2.0M | 12/1/2025 | View on chart |
| GH | ▲ Buy | Option Exercise | 15,000 | $429K | 12/1/2025 | View on chart |
| GH | ▲ Buy | Option Exercise | 35,000 | $705K | 12/1/2025 | View on chart |
| GH | ▼ Sell | Open Market | 23,974 | $2.5M | 12/1/2025 | View on chart |
| GH | ▼ Sell | Open Market | 6,786 | $725K | 12/1/2025 | View on chart |
| GH | ▼ Sell | Open Market | 664 | $72K | 12/1/2025 | View on chart |
| GH | ▼ Sell | Open Market | 1,923 | $203K | 12/1/2025 | View on chart |
| GH | ▼ Sell | Open Market | 2,444 | $260K | 12/1/2025 | View on chart |
| GH | ▼ Sell | Open Market | 800 | $86K | 12/1/2025 | View on chart |
| GH | ▲ Buy | Option Exercise | 10,477 | $0 | 10/1/2025 | View on chart |
| GH | ▼ Sell | Tax Withholding | 5,310 | $333K | 10/1/2025 | View on chart |
| GH | ▲ Buy | Option Exercise | 14,894 | $0 | 3/1/2025 | View on chart |
| GH | ▼ Sell | Tax Withholding | 6,565 | $279K | 3/1/2025 | View on chart |
| GH | ▲ Buy | Option Exercise | 17,378 | $0 | 1/15/2025 | View on chart |
| GH | ▼ Sell | Tax Withholding | 6,420 | $241K | 1/15/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Guardant Health Wins Patent Ruling, Morgan Stanley Lifts Target
Guardant Health secured a favorable decision from the U.S. Patent Trial and Appeal Board, which rejected a challenge to its core duplex sequencing patent. This legal win supports the company's position in the growing liquid biopsy market. Additionally, Morgan Stanley maintained an Overweight rating and raised its price target to $200, citing strong fundamentals in the diagnostics sector.
Guardant Health Wins Patent Ruling, Morgan Stanley Lifts Target. Guardant Health secured a favorable decision from the U.S. Patent Trial and Appeal Board, which rejected a challenge to its core duplex sequencing patent. This legal win supports the company's position in the growing liquid biopsy market. Additionally, Morgan Stanley maintained an Overweight rating and raised its price target to $200, citing strong fundamentals in the diagnostics sector.